Outcome analysis and cost assessment in immunologic disorders

Area of Science:

• Immunology
• Pharmacoeconomics
• Biologic Therapies

Background:

• Novel biologic agents are increasingly used to modulate immune responses for various medical conditions.
• Limited data exists on the cost-effectiveness of these crucial therapies.
• Two examples, interferon gamma and intravenous immunoglobulin, are examined.

Purpose of the Study:

• To evaluate the cost-effectiveness of novel biologic agents in treating immune-related diseases.
• To analyze the economic impact of interferon gamma for chronic granulomatous disease.
• To assess the cost-benefit of intravenous immunoglobulin for antibody deficiency.

Main Methods:

• Review of existing literature and cost data for biologic agents.
• Analysis of projected cost savings versus treatment expenses.
• Estimation of illness reduction rates associated with therapies.

Main Results:

• Interferon gamma (IFN-γ) treatment for chronic granulomatous disease showed a 69%-76% reduction in serious illness, with potential cost offsets from reduced infections.
• Intravenous immunoglobulin (IVIg) significantly reduces serious illness in antibody deficiency, with savings from fewer hospital admissions and organ damage.
• Significant cost variations exist for IVIg due to drug and infusion service pricing.

Conclusions:

• Biologic agents like IFN-γ and IVIg are vital for managing immune-related diseases, demonstrating significant clinical benefits.
• The cost-effectiveness of these therapies is promising, with potential for long-term savings through reduced healthcare utilization.
• Further economic analysis is needed, especially for IVIg, to optimize treatment strategies and manage costs effectively.